Literature DB >> 7508138

Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes.

K Iwasaki1, H Matsuda, K Nagase, T Shiraga, Y Tokuma, K Uchida.   

Abstract

We investigated the effects of 23 drugs on the metabolism of FK506 by human liver microsomes. Acyclovir, amphotericin B, cefixime, cefotaxime, ciprofloxacin, cyclosporin A, diltiazem, enoxacin, erythromycin, ethinyl estradiol, fluconazole, fosfomycin, kanamycin, lincomycin, loxoprofen, minocyclin, nifedipine, nilvadipine, norethindrone, ofloxacin, phenobarbital, prednisolone, or rifampicin was added to the reaction media at equimolar or at ten times an excess molar ratio of the substrate concentration; their effects on FK506 metabolism were examined. Drugs known to be the substrate of cytochrome P-450 3A inhibited the metabolism of FK506, and among the drugs tested, the inhibition by cyclosporin A and nifedipine was the strongest.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508138

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  19 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Decreased tacrolimus levels after administration of rifampin to a patient with renal transplant.

Authors:  Heather Naylor; Jenna Robichaud
Journal:  Can J Hosp Pharm       Date:  2013-11

3.  Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.

Authors:  S R Katari; M Magnone; R Shapiro; M Jordan; V Scantlebury; C Vivas; A Gritsch; J McCauley; T Starzl; A J Demetris; P S Randhawa
Journal:  Clin Transplant       Date:  1997-06       Impact factor: 2.863

4.  Estimation of minimum whole-blood tacrolimus concentration for therapeutic drug monitoring with plasma prednisolone concentration: A retrospective cohort study in Japanese kidney transplant recipients.

Authors:  Nobuyuki Sugioka; Akiko Matsushita; Takatoshi Kokuhu; Masahiko Okamoto; Norio Yoshimura; Yukako Ito; Nobuhito Shibata; Kanji Takada
Journal:  Curr Ther Res Clin Exp       Date:  2006-03

Review 5.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

8.  Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.

Authors:  Raman Venkataramanan; Shimin Zang; Timothy Gayowski; Nina Singh
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 9.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Authors:  Dirk R J Kuypers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.